AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10364864 — intervention group
Group type: COMPARATOR
Intervention: metoclopramide (10 mg)
Number of subjects: 160
Study 10364864 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 160
Study 9133308 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis with streptokinase 1.5 million IU plus oral aspirin 150 mg OD (n = 12)
Number of subjects: 21
Study 9133308 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 9)
Number of subjects: 21
Study 1991632 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound
Number of subjects: 52
Study 1991632 — intervention group
Group type: COMPARATOR
Intervention: Computed tomography
Number of subjects: 52
Study 6852623 — intervention group
Group type: EXPERIMENTAL
Intervention: D-penicillamine (600 mg/day)
Number of subjects: 21
Study 6852623 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (5 mg/day)
Number of subjects: 21
Study 6852623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 6852623 — intervention group
Group type: COMPARATOR
Intervention: No treatment after D-penicillamine or medroxyprogesterone
Number of subjects: 21
Study 31377321 — intervention group
Group type: EXPERIMENTAL
Intervention: Pleasure-oriented messages
Number of subjects: 198
Study 31377321 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-oriented messages
Number of subjects: 198
Study 31377321 — intervention group
Group type: COMPARATOR
Intervention: Control group (no leaflet)
Number of subjects: 198
Study 30485297 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based, self-managed moderate intensity walking intervention for 12 weeks
Number of subjects: 50
Study 30485297 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 50
Study 27189284 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg subcutaneous dose
Number of subjects: 119
Study 27189284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 24589307 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal infusion of catumaxomab after complete resection of all macroscopic disease.
Number of subjects: 0
Study 24589307 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal infusion of catumaxomab with different total doses administered in each of the 2 arms.
Number of subjects: 0
Study 21546443 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate (10 mg elemental zinc)
Number of subjects: 91
Study 21546443 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 20973713 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine treatment for 12 weeks
Number of subjects: 168
Study 17948207 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional weight loss treatment
Number of subjects: 251
Study 17948207 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity surgery (gastric banding)
Number of subjects: 251
Study 17948207 — intervention group
Group type: COMPARATOR
Intervention: Normal-weight individuals
Number of subjects: 251
Study 17948207 — intervention group
Group type: COMPARATOR
Intervention: Obese individuals not participating in weight loss treatment
Number of subjects: 251
Study 17948207 — intervention group
Group type: EXPERIMENTAL
Intervention: Disordered eating patterns diagnosed after surgery
Number of subjects: 251
Study 16262540 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Stress Management (CBSM) intervention, 10-week duration, n = 31
Number of subjects: 49
Study 16262540 — intervention group
Group type: COMPARATOR
Intervention: Modified wait-list control condition, n = 18
Number of subjects: 49
Study 12003113 — intervention group
Group type: EXPERIMENTAL
Intervention: Case Management (CM)
Number of subjects: 0
Study 12003113 — intervention group
Group type: COMPARATOR
Intervention: No Case Management (No‐CM)
Number of subjects: 0
Study 10601130 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiol group alkylation with N-ethylmaleimide (NEM) in untreated erythrocytes from EHT-FH patients
Number of subjects: 0
Study 10601130 — intervention group
Group type: COMPARATOR
Intervention: Thiol group alkylation with N-ethylmaleimide (NEM) in normal erythrocytes
Number of subjects: 0
Study 10601130 — intervention group
Group type: COMPARATOR
Intervention: Untreated erythrocytes from EHT-FH patients
Number of subjects: 0
Study 10601130 — intervention group
Group type: COMPARATOR
Intervention: Normal control erythrocytes
Number of subjects: 0
Study 7860761 — intervention group
Group type: EXPERIMENTAL
Intervention: IDDM subjects
Number of subjects: 15
Study 7860761 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 15
Study 2010700 — intervention group
Group type: EXPERIMENTAL
Intervention: SAVAS technique
Number of subjects: 107
Study 2010700 — intervention group
Group type: COMPARATOR
Intervention: Compression sclerotherapy (CS)
Number of subjects: 107
Study 2010700 — intervention group
Group type: COMPARATOR
Intervention: Dentist's technique (DT)
Number of subjects: 107
Study 7200319 — intervention group
Group type: EXPERIMENTAL
Intervention: Lightly hydrogenated soy oil
Number of subjects: 24
Study 7200319 — intervention group
Group type: COMPARATOR
Intervention: Corn oil
Number of subjects: 24
Study 7200319 — intervention group
Group type: COMPARATOR
Intervention: Unhydrogenated soy oil
Number of subjects: 24
Study 7200319 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyunsaturated fat diets
Number of subjects: 24
Study 30799396 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose oral prednisolone for 3 days (PSL 3)
Number of subjects: 44
Study 30799396 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose oral prednisolone for 7 days (PSL 7)
Number of subjects: 44
Study 30799396 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose oral prednisolone (both groups)
Number of subjects: 44
Study 27773929 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Number of subjects: 252
Study 27773929 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study 26013187 — intervention group
Group type: EXPERIMENTAL
Intervention: febuxostat 80 mg/day
Number of subjects: 504
Study 26013187 — intervention group
Group type: EXPERIMENTAL
Intervention: febuxostat 40 mg/day
Number of subjects: 504
Study 26013187 — intervention group
Group type: COMPARATOR
Intervention: allopurinol 300 mg/day
Number of subjects: 504
Study 26013187 — intervention group
Group type: COMPARATOR
Intervention: all groups
Number of subjects: 504
Study 25411289 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange maize (biofortified)
Number of subjects: 140
Study 25411289 — intervention group
Group type: EXPERIMENTAL
Intervention: VA+ (white maize with 400 μg retinol activity equivalents in oil)
Number of subjects: 140
Study 25411289 — intervention group
Group type: COMPARATOR
Intervention: VA- (white maize with placebo oil)
Number of subjects: 140
Study 22464779 — intervention group
Group type: EXPERIMENTAL
Intervention: LAM + ADV combination therapy
Number of subjects: 174
Study 22464779 — intervention group
Group type: COMPARATOR
Intervention: LAM mono-therapy
Number of subjects: 174
Study 22464779 — intervention group
Group type: COMPARATOR
Intervention: ADV mono-therapy
Number of subjects: 174
Study 19387976 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-delayed capsule formulation with 20% HPMC
Number of subjects: 8
Study 19387976 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-delayed capsule formulation with 24% HPMC
Number of subjects: 8
Study 19387976 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-delayed capsule formulation with 35% HPMC
Number of subjects: 8
Study 19387976 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondisintegrating riboflavin tablet (used in pulsed release study)
Number of subjects: 8
Study 17320942 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual reminder function (AVRF)
Number of subjects: 110
Study 17320942 — intervention group
Group type: COMPARATOR
Intervention: Control group (no AVRF)
Number of subjects: 110
Study 15330916 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal bolus infusions of 5 ml of acid
Number of subjects: 22
Study 15330916 — intervention group
Group type: COMPARATOR
Intervention: Duodenal bolus infusions of normal saline
Number of subjects: 22
Study 15330916 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (5‐HT(3) receptor antagonist)
Number of subjects: 22
Study 15330916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 10738704 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid
Number of subjects: 0
Study 10738704 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth factors (basic fibroblast growth factor, transforming growth factor, platelet‐derived growth factor, epidermal growth factor)
Number of subjects: 0
Study 10738704 — intervention group
Group type: COMPARATOR
Intervention: Control cells (FR control)
Number of subjects: 0
Study 9390746 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant canarypox virus expressing gp160MN or recombinant gp160MN/LAI
Number of subjects: 0
Study 9390746 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime-boost regimen using canarypox expressing gp160 followed by rgp160 boost
Number of subjects: 0
Study 9390746 — intervention group
Group type: EXPERIMENTAL
Intervention: Boost with V3 synthetic peptide
Number of subjects: 0
Study 9390746 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime-boost regimen using canarypox recombinants expressing gp160 or gp120 and purified rgp160
Number of subjects: 0
Study 9390746 — intervention group
Group type: EXPERIMENTAL
Intervention: V3 synthetic peptide boost
Number of subjects: 0
Study 1607978 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural corticosteroids (40 mg methylprednisolone acetate)
Number of subjects: 84
Study 1607978 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 84
Study 3982742 — intervention group
Group type: EXPERIMENTAL
Intervention: External cephalic version under tocolysis
Number of subjects: 148
Study 3982742 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful external cephalic version
Number of subjects: 148
Study 3982742 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful external cephalic version with vertex presentation
Number of subjects: 148
Study 3982742 — intervention group
Group type: COMPARATOR
Intervention: Control group (randomized)
Number of subjects: 148
Study 3069500 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised test for assessment of PVD
Number of subjects: 200
Study 3069500 — intervention group
Group type: COMPARATOR
Intervention: Skilled clinician diagnosis
Number of subjects: 200
Study 3069500 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified computer protocol for non-vascular diagnosis
Number of subjects: 200
Study 31127753 — intervention group
Group type: EXPERIMENTAL
Intervention: Maitland's oscillatory mobilization
Number of subjects: 46
Study 31127753 — intervention group
Group type: COMPARATOR
Intervention: Kaltenborn's sustained stretch mobilization
Number of subjects: 46
Study 30769056 — intervention group
Group type: EXPERIMENTAL
Intervention: Spot stenting
Number of subjects: 125
Study 30769056 — intervention group
Group type: COMPARATOR
Intervention: Long stenting
Number of subjects: 125
Study 28689524 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised Structured Aerobic Exercise Training (SSAET) program, routine medication, and dietary plan
Number of subjects: 102
Study 28689524 — intervention group
Group type: COMPARATOR
Intervention: Routine medication and dietary plan
Number of subjects: 102
Study 26386974 — intervention group
Group type: EXPERIMENTAL
Intervention: Recline Exercise (RE)
Number of subjects: 40
Study 26386974 — intervention group
Group type: COMPARATOR
Intervention: Head Lift Exercise (HLE)
Number of subjects: 40
Study 23393214 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Medical Clinics (GMC)
Number of subjects: 239
Study 23393214 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 239
Study 21165658 — intervention group
Group type: EXPERIMENTAL
Intervention: Local bone graft
Number of subjects: 82
Study 21165658 — intervention group
Group type: COMPARATOR
Intervention: Iliac crest bone graft (ICBG)
Number of subjects: 82
Study 18773134 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal vault suspension after hysterectomy (n = 32)
Number of subjects: 6214
Study 18773134 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 236)
Number of subjects: 6214
Study 18773134 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative prolapse
Number of subjects: 6214
Study 18773134 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual activity
Number of subjects: 6214
Study 18773134 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal hysterectomy
Number of subjects: 6214
Study 17575757 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixation of the mesh (Group A)
Number of subjects: 40
Study 17575757 — intervention group
Group type: COMPARATOR
Intervention: No fixation of the mesh (Group B)
Number of subjects: 40
Study 12950574 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gel (CG), coronally unsealed
Number of subjects: 80
Study 12950574 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide (CaOH2), coronally unsealed
Number of subjects: 80
Study 12950574 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide + 2% chlorhexidine gel (CaOH2 + CG), coronally unsealed
Number of subjects: 80
Study 12950574 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gel (CG) + coronal seal
Number of subjects: 80
Study 12950574 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide (CaOH2) + coronal seal
Number of subjects: 80
Study 12950574 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide + 2% chlorhexidine gel (CG + CaOH2) + coronal seal
Number of subjects: 80
Study 12950574 — intervention group
Group type: EXPERIMENTAL
Intervention: No intracanal medicament + coronal seal
Number of subjects: 80
Study 12950574 — intervention group
Group type: COMPARATOR
Intervention: Positive control group (PC) - no treatment, coronally unsealed
Number of subjects: 80
Study 12950574 — intervention group
Group type: COMPARATOR
Intervention: Negative control group (NC) - intact crowns
Number of subjects: 80
Study 11023562 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound (EUS)
Number of subjects: 75
Study 11023562 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound (EUS) with added parameter 'irregular tumor‐vessel relationship'
Number of subjects: 75
Study 11023562 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound (EUS) parameters for portal venous involvement
Number of subjects: 75
Study 8723171 — intervention group
Group type: EXPERIMENTAL
Intervention: Pranidipine 1 mg od
Number of subjects: 199
Study 8723171 — intervention group
Group type: EXPERIMENTAL
Intervention: Pranidipine 2 mg od
Number of subjects: 199
Study 8723171 — intervention group
Group type: EXPERIMENTAL
Intervention: Pranidipine 4 mg od
Number of subjects: 199
Study 8723171 — intervention group
Group type: EXPERIMENTAL
Intervention: Pranidipine 8 mg od
Number of subjects: 199
Study 8723171 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study 1362887 — intervention group
Group type: EXPERIMENTAL
Intervention: L-659,066 (8 mg administered by short intravenous infusion)
Number of subjects: 0
Study 3907286 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulants for one month
Number of subjects: 135
Study 3907286 — intervention group
Group type: COMPARATOR
Intervention: Oral anticoagulants for six months
Number of subjects: 135
Study 29069291 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training
Number of subjects: 49
Study 29069291 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention
Number of subjects: 49
Study 29069291 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination intervention
Number of subjects: 49
Study 29069291 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training
Number of subjects: 49
Study 29069291 — intervention group
Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 49
Study 27676396 — intervention group
Group type: COMPARATOR
Intervention: 0 mg/d CAP from chili powder
Number of subjects: 12
Study 27676396 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/d CAP from chili powder
Number of subjects: 12
Study 27676396 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/d CAP from chili powder
Number of subjects: 12
Study 25362668 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobility platform
Number of subjects: 71
Study 25362668 — intervention group
Group type: COMPARATOR
Intervention: Standard equipment
Number of subjects: 71
Study 22495998 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients (type 2 diabetes)
Number of subjects: 98
Study 22495998 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 98
Study 20538121 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMZ)
Number of subjects: 60
Study 20538121 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 18575308 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro Seal varnish applied before sealant
Number of subjects: 60
Study 18575308 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro Seal varnish applied after sealant
Number of subjects: 60
Study 18575308 — intervention group
Group type: COMPARATOR
Intervention: Control group (sealant only)
Number of subjects: 60
Study 16019866 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group (30 patients) trained 3 times a week during 3 months and once a week during 6 months.
Number of subjects: 43
Study 16019866 — intervention group
Group type: COMPARATOR
Intervention: Control group (13 patients)
Number of subjects: 43
Study 12425363 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin-A (btA) injection with conventional physical therapy
Number of subjects: 35
Study 12425363 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy only
Number of subjects: 35
Study 10771458 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 400 mg once daily for 6 days
Number of subjects: 14
Study 10771458 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 8610920 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast cancer treatment in black women
Number of subjects: 0
Study 8610920 — intervention group
Group type: COMPARATOR
Intervention: Breast cancer diagnosis
Number of subjects: 0
Study 8610920 — intervention group
Group type: COMPARATOR
Intervention: Tumor biology
Number of subjects: 0
Study 1356277 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpidem (mean dose 112.5 mg daily)
Number of subjects: 23
Study 1356277 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam (mean 3.5 mg daily)
Number of subjects: 23
Study 3895962 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose treatment with 500 mg clotrimazole vaginal tablet
Number of subjects: 115
Study 3895962 — intervention group
Group type: COMPARATOR
Intervention: 3-day treatment with two 100 mg vaginal tablets administered daily
Number of subjects: 115
Study 30430760 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic method
Number of subjects: 33
Study 30430760 — intervention group
Group type: COMPARATOR
Intervention: Microscopic method
Number of subjects: 33
Study 30008052 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-Crystal of Tramadol-Celecoxib (CTC) under fed conditions
Number of subjects: 36
Study 30008052 — intervention group
Group type: COMPARATOR
Intervention: Co-Crystal of Tramadol-Celecoxib (CTC) under fasting conditions
Number of subjects: 36
Study 27081705 — intervention group
Group type: EXPERIMENTAL
Intervention: NeoHeal
Number of subjects: 30
Study 27081705 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 30
Study 26160058 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 7) - integrated content on physical activity (PA) and sedentary behavior (SB) into health education (HE) lessons
Number of subjects: 14
Study 26160058 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (n = 7) - standard HE lessons
Number of subjects: 14
Study 22930241 — intervention group
Group type: EXPERIMENTAL
Intervention: BMD reports from reading specialists
Number of subjects: 48
Study 22930241 — intervention group
Group type: EXPERIMENTAL
Intervention: Research team assessment of fracture risk
Number of subjects: 48
Study 20497921 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan (TCC)
Number of subjects: 16
Study 20497921 — intervention group
Group type: COMPARATOR
Intervention: Standard support therapy (ST)
Number of subjects: 16
Study 18305069 — intervention group
Group type: COMPARATOR
Intervention: Open suction (OS)
Number of subjects: 30
Study 18305069 — intervention group
Group type: COMPARATOR
Intervention: Closed suction (CS)
Number of subjects: 30
Study 16178478 — intervention group
Group type: EXPERIMENTAL
Intervention: Icodextrin (ID)
Number of subjects: 22
Study 16178478 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acids (AA)
Number of subjects: 22
Study 16178478 — intervention group
Group type: COMPARATOR
Intervention: Glucose-only-based solutions
Number of subjects: 22
Study 12546607 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium, 75 mg twice daily
Number of subjects: 82
Study 12546607 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen, 1000 mg 4 times daily
Number of subjects: 82
Study 12546607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 10485533 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposable hydrogel lenses on a 6-night extended wear and replacement schedule
Number of subjects: 330
Study 7561223 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-hourly administration of controlled-release morphine (MS Contin)
Number of subjects: 19
Study 7561223 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-hourly administration of controlled-release morphine (MS Contin)
Number of subjects: 19
Study 7561223 — intervention group
Group type: COMPARATOR
Intervention: 8-hourly and 12-hourly administration of controlled-release morphine (MS Contin)
Number of subjects: 19
Study 1782724 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO
Number of subjects: 8
Study 1782724 — intervention group
Group type: COMPARATOR
Intervention: Control (unchanged EPO prescription)
Number of subjects: 8
Study 6907170 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 19